Sort   by:  
 Page size 
UnknownGermline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
Not available
S-EPMC5815624 | biostudies-literature
UnknownEverolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial.
Not available
S-EPMC5037621 | biostudies-literature
UnknownIBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Not available
S-EPMC9392694 | biostudies-literature
UnknownROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Not available
S-EPMC11224110 | biostudies-literature
UnknownDepth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Not available
S-EPMC5568033 | biostudies-literature
UnknownReal world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.
Not available
S-EPMC12006532 | biostudies-literature
Sort   by:  
 Page size